Donavan Cheng is the Chief Science and Technology Officer at Ambry Genetics. He graduated with a PhD in Biomedical Engineering from Johns Hopkins University School of Medicine. In this role, he manages the Informatics and R&D efforts at Ambry. For informatics, he leads a team of bioinformaticians, software development and systems engineers to innovate, architect, and develop pipelines and applications for Ambry’s product portfolio. Donavan leverages his experience in assay development and molecular technologies to advance the company's R&D efforts. Prior to joining Ambry, Donavan worked at Guardant Health, where he led bioinformatics and assay development efforts for minimal residual disease. At Illumina, he was responsible for product management in Population Genomics/Genetic Health, as well as the BaseSpace Suite of SaaS/PaaS products. Donavan specializes in bioinformatics workflows for identifying targets and biomarkers from high-dimensional molecular profiling data, as well as the analytical validation of NGS-based molecular diagnostics.